12 patents
Utility
Dosing regimens of PKC activators
28 Nov 23
Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks.
Daniel L. Alkon
Filed: 1 Oct 20
Utility
PKC-activating compounds for the treatment of neurodegenerative diseases
21 Nov 23
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Thomas J. Nelson, Daniel L. Alkon
Filed: 6 Jul 22
Utility
Method of Inducing Synaptogenesis by Administering Angiotensin and Analogues Thereof
5 Jan 23
A method for inducing synaptogenesis in a subject having a neurodegenerative disease, the method comprising administering an angiotensin or analogue thereof in a therapeutically effective amount to induce synaptogenesis in said subject.
Daniel L. ALKON
Filed: 29 Jun 21
Utility
Pkc-activating Compounds for the Treatment of Neurodegenerative Diseases
10 Nov 22
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Thomas J. NELSON, Daniel L. ALKON
Filed: 6 Jul 22
Utility
PKC-activating compounds for the treatment of neurodegenerative diseases
19 Jul 22
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Thomas J. Nelson, Daniel L. Alkon
Filed: 17 Jun 20
Utility
Treatment of Amyotrophic Lateral Sclerosis Using PKC Activators
16 Jun 22
A method for treating or preventing amyotrophic lateral sclerosis (ALS) or other motor neuron disease in a subject, the method comprising administering to the subject a PKC activating compound (e.g., a bryostatin, such as bryostatin-1, or a bryolog) in a therapeutically effective amount to treat or prevent the motor neuron disease by activating PKC in the subject.
Daniel L. ALKON
Filed: 15 Dec 21
Utility
Methods of Treating and Preventing Neurodegenerative Diseases with HGF Activating Compounds
5 May 22
A method for treating or preventing a neurodegenerative disease in a subject, the method comprising administering an HGF activating compound in a therapeutically effective amount to treat or prevent the neurodegenerative disease by activating HGF in the subject.
Daniel L. ALKON
Filed: 30 Dec 20
Utility
Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
15 Mar 22
The present disclosure describes novel PKC-ε activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof.
Thomas J. Nelson, Daniel L. Alkon
Filed: 25 Jan 19
Utility
Methods and Compositions for Treatment of Alzheimer's Disease and Other Neurodegenerative Disorders
7 Oct 21
A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
Daniel L. ALKON
Filed: 18 Jun 21
Utility
Methods for inducing synaptogenesis with synaptic growth factor activating compounds
29 Jun 21
A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
Daniel L. Alkon
Filed: 28 Jun 20
Utility
Methods and Compositions for Treatment of Alzheimer's Disease and Other Neurodegenerative Disorders
14 Oct 20
A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
Daniel L. Alkon
Filed: 27 Jun 20
Utility
Methods and Compositions for Treatment of Alzheimer's Disease
20 Nov 19
A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.
Daniel L. Alkon
Filed: 16 May 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first